MedTrace Logo

Study Evaluating UCART20x22 in B-Cell Non-Hodgkin Lymphoma

NCT05607420 · Status: RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2025-08-24

No results posted yet for this study

Summary

First-in-human, open-label, dose-finding and dose-expansion study of UCART20x22 administered intravenously in subjects with relapsed or refractory B-Cell Non-Hodgkin Lymphoma (B-NHL). The purpose of this study is to evaluate the safety and clinical activity of UCART20x22 and determine the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D).

Conditions

  • B-cell Non-Hodgkin Lymphoma (B-NHL)

Interventions

BIOLOGICAL

UCART20x22

Allogeneic engineered T-cells expressing anti-CD20 and anti-CD22 Chimeric Antigen Receptors given following a lymphodepletion regimen

BIOLOGICAL

CLLS52

A monoclonal antibody that recognizes a CD52 antigen

Sponsors & Collaborators

  • Cellectis S.A.

    lead INDUSTRY

Principal Investigators

  • Jeremy Abramson, MD · Harvard Medical School - Massachusetts General

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-11-01
Primary Completion
2027-08-31
Completion
2027-08-31
FDA Drug
Yes

Countries

  • United States
  • France
  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05607420 on ClinicalTrials.gov